Clinical Trial

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Name: Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC — clinical trial record (NCT05608213)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).

Trial Details

NCT Number	NCT05608213
Lead Sponsor	Second Affiliated Hospital of Guangzhou Medical University
Conditions	Hepatocellular Carcinoma Non-resectable
Enrollment	187 participants
Start Date	2022-11-02
Primary Completion	2026-10-31 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2022-11-08